These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 21199775)

  • 21. Pharmacological approaches to the management of alcohol addiction.
    Addolorato G; Armuzzi A; Gasbarrini G; De Lorenzi G; Ancona C; Abenavoli L; Parente A; Leggio L; Capristo E; Greco AV; Janiri L; Pozzi G; Taranto C; Caputo F; Bernardi M; Stefanini GF; Foschi FG;
    Eur Rev Med Pharmacol Sci; 2002; 6(5):89-97. PubMed ID: 12776801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research strategies to assess pharmacotherapies for alcoholism.
    Naranjo CA; Bremner KE; Poulos CX
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 May; 20(4):543-59. PubMed ID: 8843484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence.
    Mason BJ; Heyser CJ
    CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):23-32. PubMed ID: 20201812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropharmacology of Alcohol Addiction with Special Emphasis on Proteomic Approaches for Identification of Novel Therapeutic Targets.
    Ray SK; Mukherjee S
    Curr Neuropharmacol; 2023; 21(1):119-132. PubMed ID: 35959616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical and clinical studies on naltrexone: what have they taught each other?
    Froehlich J; O'Malley S; Hyytiä P; Davidson D; Farren C
    Alcohol Clin Exp Res; 2003 Mar; 27(3):533-9. PubMed ID: 12658121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice.
    Litten RZ; Falk DE; Ryan ML; Fertig J; Leggio L
    Alcohol Clin Exp Res; 2020 Jan; 44(1):23-35. PubMed ID: 31803968
    [No Abstract]   [Full Text] [Related]  

  • 27. Combining psychosocial treatment with pharmacotherapy for alcohol dependence.
    Weiss RD; Kueppenbender KD
    J Clin Psychopharmacol; 2006 Dec; 26 Suppl 1():S37-42. PubMed ID: 17114954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacotherapy of dual substance abuse and dependence.
    Kenna GA; Nielsen DM; Mello P; Schiesl A; Swift RM
    CNS Drugs; 2007; 21(3):213-37. PubMed ID: 17338593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in nonhuman primate alcohol abuse and alcoholism research.
    Grant KA; Bennett AJ
    Pharmacol Ther; 2003 Dec; 100(3):235-55. PubMed ID: 14652112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in translational pharmacological investigations in identifying and validating molecular targets of natural product anticancer agents.
    Yu J; Nag SA; Zhang R
    Curr Cancer Drug Targets; 2013 Jun; 13(5):596-609. PubMed ID: 23597194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies.
    Morley KC; Perry CJ; Watt J; Hurzeler T; Leggio L; Lawrence AJ; Haber P
    Expert Opin Pharmacother; 2021 Jul; 22(10):1291-1303. PubMed ID: 33615945
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacotherapy for Co-Occurring Alcohol Use Disorder and Post-Traumatic Stress Disorder: Targeting the Opioidergic, Noradrenergic, Serotonergic, and GABAergic/Glutamatergic Systems.
    Verplaetse TL; McKee SA; Petrakis IL
    Alcohol Res; 2018; 39(2):193-205. PubMed ID: 31198658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of human laboratory models to pharmacotherapy development for alcohol dependence.
    Ray LA; Hutchison KE; Tartter M
    Curr Pharm Des; 2010; 16(19):2149-58. PubMed ID: 20482505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrative Analysis of Genetic, Genomic, and Phenotypic Data for Ethanol Behaviors: A Network-Based Pipeline for Identifying Mechanisms and Potential Drug Targets.
    Bogenpohl JW; Mignogna KM; Smith ML; Miles MF
    Methods Mol Biol; 2017; 1488():531-549. PubMed ID: 27933543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Animal Model of Alcohol Dependence to Screen Medications for Treating Alcoholism.
    Becker HC; Lopez MF
    Int Rev Neurobiol; 2016; 126():157-77. PubMed ID: 27055614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research.
    Kranzler HR
    Alcohol Alcohol; 2000; 35(6):537-47. PubMed ID: 11093959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic potential of NMDA receptor antagonists in the treatment of alcohol and substance use disorders.
    Bisaga A; Popik P; Bespalov AY; Danysz W
    Expert Opin Investig Drugs; 2000 Oct; 9(10):2233-48. PubMed ID: 11060803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of serotonin (5-HT) and opiate-based drugs in the pharmacotherapy of alcohol dependence: an overview of the preclinical data.
    Lê AD; Tomkins DM; Sellers EM
    Alcohol Alcohol Suppl; 1996 Mar; 31(1):27-32. PubMed ID: 9845035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic treatment of alcoholism.
    Anton RF; Schacht JP; Book SW
    Handb Clin Neurol; 2014; 125():527-42. PubMed ID: 25307594
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.